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ABSTRACT
This study aims at understanding the individual and community-level characteristics that influenced par-
ticipation in two consecutive vaccine trials (typhoid and cholera) in urban slums of Kolkata, India. The 
study area was divided into 80 geographic clusters (communities), with 59,533 subjects aged ≥2 years for 
analysis. A multi-level model was employed in which the individuals were seen nested within the cluster. 
Rates of participation in both the trials were nearly the same; those who participated in the initial trial 
were likely to participate in the subsequent cholera vaccine trial. Communities with predominantly Hindu 
population, lower percentage of households with an educated household head, or lower percentage of 
households owning a motorbike had higher participation than their counterparts. At individual scale, 
higher participation was observed among younger subjects, females, and individuals from households with 
a household head who had no or minimal education. Geographic patterns were also observed in participa-
tion in the trials. The results illustrated that participation in the trial was mostly influenced by various indi-
vidual and community-level factors, which need to be addressed for a successful vaccination campaign. 
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INTRODUCTION
Immunization is one of the most cost-effective 
strategies to prevent millions of infectious disease 
episodes and deaths around the world. Phase III 
and IV vaccine trials are crucial in the licensure of 
newly-developed vaccines or deployment of un-
derused vaccines in poor countries. Phase III ran-
domized controlled trials enroll thousands of sub-
jects to provide rigorous evidence about vaccine 
protection against naturally-occurring infections. 
Results of phase IV studies, which may be even larg-
er in size and longer in duration of follow-up, are 
used for evaluating the safety and effectiveness of 
licensed vaccines when given under public-health   
conditions. The large numbers of participants, pros- 
pective nature of the studies, lengthy duration of 
follow-up, quality control, and quality-assurance 
procedures make these trials time-, labour- and 
cost-intensive.
The success of large phase III and IV trials and mass-
vaccination campaigns in developing-country 
populations requires information dissemination, 
discussions with community leaders, and encour-
agement of community participation. Despite 
these efforts, not all members of a population may 
wish to participate in the vaccine trial or the cam-
paign. Each individual and family need to weigh 
perceived risks and benefits, reflect on the value of 
participation, and consider potential consequences 
(1). In some developing-country societies, false per-
ceptions and irrational fears about vaccines may 
appear when conducting field trials and mass-vac-
cination campaigns. Such a situation occurred in 
India during the 1970s when vaccines were associ-
ated with fears of family-planning agenda (2,3). In 
these types of situation, a vaccine trial or a cam-
paign may become vulnerable to misperceptions 
and fears, which can greatly influence community 
participation.
Typhoid fever and cholera are endemic in India and 
are persistent problems in Kolkata (4). India, along 
with some Asian countries, is considered a high ty-
phoid-incidence area, with a crude incidence of 622 
cases per 100,000 people per year (5). The typhoid 
Vi polysaccharide vaccine is licensed in India but 
its cost precludes it from being used in the public-Ali M et al. Community participation in vaccination trials
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health setting. Cholera has a tenacious grip on the 
state of West Bengal where it is endemic. There was 
no licensed cholera vaccine in India until Febru-
ary 2009. The International Vaccine Institute, with 
funding from the Bill & Melinda Gates Foundation, 
aims at intro  ducing vaccines against these two en-
teric diseases into the public-health programmes of 
developing countries (6). In this paper, we sought 
to assess the factors influencing individual and 
community participations, by analyzing data from 
two consecutive vaccine trials through spatial and 
multi-level techniques. 
MATERIALS AND METHODS
Study setting and sample
The study was conducted in urban slum commu-
nities in Kolkata, capital of the state of West Ben-
gal. Kolkata, the third largest city in India, has 14 
million inhabitants living within an area of 1,450 
sq km, making it one of the world’s most densely-
populated cities. The Kolkata Municipal Corpora-
tion consists of 141 civic administrative units called 
ward, with each ward having an office responsible 
for public health supervised by a medical officer. 
The study site comprises two contiguous wards (29 
and 30) and encompasses an area of 0.99 sq km. 
Residents live in homes tightly-spaced together 
along winding sewage-littered pathways, and they 
rely on shared toilets and drinking-water (7). Seven 
referral government hospitals, various traditional 
practitioners, private medical clinics of qualified 
and unqualified physicians, and private nursing 
homes provide healthcare in Kolkata. Five health 
clinics (Fig.) were set up in the study area for pri-
mary care, and cases were referred to the Infectious 
Diseases Hospital (IDH), which is within a few km 
from the study site, and B.C. Roy Children Hospi-
tal, which is adjacent to the study site. 
The project staff conducted a baseline census in 
early 2002 to enumerate the people of the study 
area, which was followed by a second census one 
year later. Information on individual-level char-
acteristics, such as age, gender, level of education, 
and socioeconomic status of the household, was 
collected during the census surveys. For the cholera 
vaccine trial, the study area was expanded to in-
clude residents of the southern part of Ward 29 and 
the whole of Ward 33. There were about 67,400 
people living in the common trial area during the 
time of vaccination. However, for the purposes of 
this study, this additional area was not included in 
the analysis.  
Typhoid and cholera vaccination trials
The characteristics of the two vaccine trials are 
shown in Table 1. The new-generation Vi polysac-
charide typhoid fever vaccine (Typherix) was used 
in the typhoid vaccine trial and was donated by 
GlaxoSmithKline. This vaccine is safe, requires sin-
gle dosing, has consistent efficacy (64-77%), and 
has less strict cold-chain requirements, making the 
vaccine more adaptable for use in public-health 
settings in developing countries (8-10). Eligible par-
ticipants for the typhoid vaccine trial were healthy, 
afebrile, non-pregnant, and non-lactating residents 
who were aged two years and older. The study sub-
jects were randomized by geographical cluster to 
take either the Vi polysaccharide vaccine or the ac-
tive control hepatitis A vaccine (Havrix) and were 
blinded. Eighty clusters were defined using the 
geographic information system (GIS), which de-
fined clusters by connecting geographic features of 
households to give an average population (about 
700) in each cluster. Vaccination was conducted 
from November to December 2004.
The cholera vaccine trial used a two-dose primary 
regimen of the oral killed whole-cell bivalent (Vibrio 
cholerae O1 and O139) cholera vaccine. This vac-
cine, recently licensed in India as Shanchol (Shantha 
Biotech, Hyderabad, India), was reformulated by 
scientists of the International Vaccine Institute to 
conform to the international and WHO standards. 
Like the typhoid vaccine trial, the design of the 
cholera vaccine trial was cluster-randomized and 
double-blinded, with the Escherichia coli K12 used 
Table 1. Participation rate in typhoid and cholera vaccine trials among subjects aged two years and 
above, Kolkata, India
Participated in  
typhoid trial
Participated in cholera vaccine trial
Total
(n=59,533) Yes (n=34,730) No (n=20,210) Not illegible*
(n=4,593)
Yes 28,099 (74.6) 9,581 (25.4) 0 (0.0) 37,680
No   5,994 (28.8) 10,262 (49.2) 4,593 (22.0) 20,849
Not illegible†      637 (63.4) 367 (36.6) 0 (0.0) 1,004
Figures in parentheses indicate percentages; *Either pregnant during the vaccine campaign or migrated 
out before the cholera vaccine campaign; †Febrile, pregnant, or lactating during the typhoid vaccine 
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Fig. Local Bayes smoothing rate (%) of parti-
cipation in typhoid vaccine, cholera vac-
cine, and both trials shown in quintile 
distribution of rates, Kolkata, India 
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as placebo. In the cholera vaccine trial, the unit of 
cluster was the premise, which is pre-assigned by 
the local municipal office. Each premise consists of 
one or more contiguous households (huts or if in a 
building, single rooms) sharing latrines and water 
sources. Healthy subjects aged one year and older 
residing in the study area and women who were 
not pregnant were eligible for participating in 
the cholera trial. Recruitment for the cholera trial 
was conducted from July to September 2006 with 
a two-week gap between the first and the second 
doses.
Non-participants in the study were defined as in-
dividuals who did not present in the vaccine trial 
centres for dosing. Participants in the two trials 
were blinded to the study agent that they received 
and were also unaware of the type of agent admin-
istered according to population cluster. Since our 
aim was to determine the factors associated with 
participation in the two consecutive vaccine tri-
als, we used a common target population for both 
the trials by restricting the geographic area to the 
common study site where the typhoid trial was per-
formed and the age-group, including only residents 
aged two years and older. 
Cluster and ecological variables
In this analysis, clusters were based on the typhoid 
vaccine trial using empirically-defined geographic 
units because the clusters (premises) in the cholera 
vaccine trial were very heterogenous with regard 
to population-size that may incorporate bias in 
cluster-level variations, We then used the empiri-
cally-divided 80 geographic units for conducting 
multi-level analysis assuming that social contacts 
to be strong within such smaller geographic units. 
Individual-level data on vaccination and socioeco-
nomic status were aggregated for those 80 clusters 
to obtain ecological data for conducting the multi-
level analysis.
Empirical Bayes map
We used local Empirical Bayes estimation to map 
the spatial patterns of the vaccine coverage. The 
coverage was computed as a weighted sum of the 
rate observed at that location, and a prior mean 
was based on the first order of neighbours. The esti-
mated coverage of each cluster shrunk towards the 
mean of the first order of neighbours (11). 
Statistical analysis
Multi-level models were used for analyzing the hi-
erarchical structured data in which the individuals 
were clustered within the cluster (communities). 
This method enables investigation of the effects 
of variables measured at different levels (12,13), 
thus predicting the participation of an individual 
in the typhoid vaccine and cholera vaccine trials, 
and in the two trials adjusting for the community-
level variation of participation in the trials. Unlike Ali M et al. Community participation in vaccination trials
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estimating fixed effects only in a regression model, 
the multi-level model offers estimation of both 
fixed and random effects (14); thus, variations in 
the community level can be known and adjusted 
through employing the model. Since the diverse 
community characteristics were observed in the 
study area, we assumed considerable variations in 
vaccine uptake among communities, which led us 
to choose the multi-level model for predicting the 
factors relating to participation in the two trials. We 
used HLM for Windows version (version 6.02a) (Sci-
entific Software International, Inc., Lincolnwood, 
USA) for the multi-level (hierarchical) analysis. 
Ethics
The ethics committee of the National Institute of 
Cholera & Enteric Diseases, the Health Ministry 
Screening Committee of India, and the Interna-
tional Vaccine Institute Institutional Review Board 
approved the study protocol.
RESULTS
Of the 59,533 individuals in the common target 
population of the two trials, 1,004 and 4,593 were 
ineligible, respectively, for the typhoid vaccine and 
cholera vaccine trials; 54,940 individuals were, 
thus, included in this analysis. After excluding in-
eligible subjects, participation was 64% and 63% 
in the typhoid vaccine and cholera vaccine trials 
respectively. Table 1 shows the participation of eli-
gible subjects in either trial. Moreover, those who 
participated in the typhoid vaccine trial were more 
likely to participate in the subsequent cholera vac-
cine trial [odds ratio: 5.02; 95% confidence interval 
(CI) 4.83-5.22] compared to those who did not par-
ticipate in the typhoid vaccine trial. The individual, 
household and cluster-level characteristics of the 
participants and non-participants for the two trials 
are shown in Table 2.    
To predict the participation of an individual in the 
vaccine trials, the following three models were cre-
ated: (a) no covariates were included (null model); 
(b) inclusion of a number of fixed individual-level 
terms; and (c) inclusion of a number of fixed indi-
vidual- and cluster-level terms. The results of all the 
three models are shown in Table 3. The results of 
the unit-specified model with robust standard error 
are shown in terms of estimates and the ratios of 
the estimates to their standard errors (t-ratios). As a 
cut-off, if the ratio exceeds 2.0, the estimates are 
deemed significantly different from zero. Since the 
response variable was measured in logit scale, the 
estimates for the constants were 0.63, 0.58, and 0.10 
for typhoid vaccine, cholera vaccine, and both the 
trials respectively; when untransformed it implies 
that the probability of participation in the typhoid 
vaccine, cholera vaccine, and in both the trials for 
all individuals across all clusters was 65%, 64%, 
and 52% respectively. The results also showed the 
substantial cluster-level differences (t-ratio=11.1) 
in participation in the typhoid vaccine trial with 
a grand mean of around 0.63 and a variance of 
0.25. The cluster-level differences in participation 
in the cholera vaccine trial was also substantial (t-
ratio=12.6). However, the cluster-level difference in 
participation in both the trials was not substantial. 
Upon estimating the residuals, the worst and best 
clusters had residuals of -1.81 and 1.08 respectively 
for the typhoid vaccine trial; only 23% participated 
in the worst clusters and 85% participated in the 
best clusters. Similarly, the worst communities in 
the cholera vaccine trial achieved only 43% cover-
age, and the best communities achieved 81% cov-
erage. The trend remained the same when looking 
at coverage in both the trials (18% in the worst 
communities and 73% in the best communities). 
Model 2 included a number of fixed individual-lev-
el terms and its estimates are in Table 3. In each of 
the trials, individuals with the following character-
istics had higher participation than their counter-
parts: younger age, female, from a household with 
a non-educated household head, and low socioeco-
nomic status. Participation by Hindus was higher 
than by Muslims in the cholera vaccine trial. Indi-
viduals with a younger household head had higher 
participation rates in the typhoid vaccine and chol-
era vaccine trials compared to individuals with an 
older household head. The slight reduction of the 
cluster-level variance in Model 2 for the cholera vac-
cine trial from Model 1 indicated the slight differ-
ences in the predictor variability between clusters. 
After controlling for the individual-level character-
istics that vary from cluster to cluster, participation 
in the worst and best communities are now 37% 
and 93% respectively for the typhoid vaccine trial, 
62% and 89% respectively for the cholera vaccine 
trial, and 30% and 85% respectively for both the 
trials, which indicates a narrower range compared 
to the initial estimate from Model 1.
In Model 3, we added the cluster-level terms in ad-
dition to the individual-level terms. The estimate 
for the constant is now the log-odds of participa-
tion in a trial for the ‘average’ individual living in an 
average religiously-distributed cluster, average 
age, average percentage of males, average percent-
age of educated households, and average percent-
age of households of high socioeconomic status. 
The estimates of the individual-level fixed effects 
remained stable, except for religion (Hindu) while 
the coefficient for the extra terms showed that indi-
viduals in a Hindu- or female-dominated commu-
nity had higher participation rates in each trial and Ali M et al. Community participation in vaccination trials
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Table 2.  Characteristics of participants and non-participants in typhoid and cholera vaccine trials
Characteristics
 Participants Non-participants
% Mean  % Mean 
Typhoid (participants=37,680, non-participants=20,849)
  Age (years) 27.32          31.07         
  Male  52.55 59.12
  Hindu 61.47 51.40
  Distance (metre) from household to health outpost  158.22          148.12         
  Age (years) of household head 52.08          52.89         
  Male household head 79.28 80.62
  Educated household head* 35.43 38.34
  Household-size (no.) 7.65       7.84      
  Household owning motorbike 5.07 6.64
  % of Hindu in the cluster 61.67          50.95   
  Population age (years) in the cluster 28.83            28.22           
  % of males in the cluster 53.88            54.22           
  % of educated household heads in the cluster 36.71          35.69         
  % of households owning motorbike in the cluster 5.68      5.55    
Cholera (participants=34,730, non-participants=20,210)
  Age (years) 27.04          30.39         
  Male  50.46 59.93
  Hindu 62.29 49.93
  Distance (metre) from household to health outpost  157.59          149.19         
  Age (years) of household head 51.98          52.28         
  Male household head 79.11 81.25
  Educated household head* 35.26 37.18
  Household-size (no.) 7.61       7.98      
  Household owning motorbike 4.88 6.87
  % of Hindu in the cluster 62.35          49.99         
  Population age (years) in the cluster 28.97            27.93           
  % of males in the cluster 53.77            54.33           
  % of educated household heads in the cluster 37.17          34.60         
  % of households owning motorbike in the cluster 5.71       5.44      
Both typhoid and cholera (participants=28,099, 
non-participants=25,837) 
Age (years) 26.68          30.14         
Male  50.58 59.62
Hindu 64.60 50.73
Distance (metre) from household to health outpost  160.22          148.76         
Age (years) of household head  52.08          52.18         
Male household head 78.72 81.30
Educated household head* 35.39 36.99
Household-size (no.) 7.54       7.93      
Household owning motorbike 4.69 6.61
% of Hindu in the cluster 64.81          50.58         
Population age (years) in the cluster 29.14            28.04           
% of males in the cluster 53.74            54.25           
% of educated household heads in the cluster 37.56          34.90         
% of households owning motorbike in the cluster 5.80       5.43      
*Completed at least secondary education (10 years of schooling)Ali M et al. Community participation in vaccination trials
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 Table 3. Model estimates and ratio of estimate to standard error (in parenthesis)
Variable
Typhoid (n=58,529) Cholera (n=54,940)
Typhoid and cholera 
(n=53,936)
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Fixed-term: 
individual level    
Constant
 
0.633
(11.1)
1.574  
(7.8)
1.728   
(7.5)
0.578
(12.6)
1.243   
(8.7)
1.460   
(8.2)
0.100
(1.9)
0.882  
(4.9)
 1.101  
(4.9)
Age (years) -0.013**
(18.8) 
-0.013**
(18.8) 
-0.014**
(17.0) 
 -0.014**
(16.9) 
-0.015**
(19.4) 
-0.015**
(19.3)
Male -0.278**
(9.2) 
-0.276**
(9.1) 
-0.385**
(11.8) 
 -0.382**
(11.7) 
-0.374**
(11.1) 
-0.372**
(11.1)
Hindu -0.060
(0.4)  
-0.245
(1.2)  
0.387**
(3.0) 
 0.134
(0.7)  
0.128
(0.8)  
-0.135
(0.6) 
Distance (metre) 
to health outpost 
from household 
-0.000
(0.4)  
-0.000
(0.7)  
-0.000
(0.1)  
 
-0.000
(0.7)  
-0.000
(0.0)  
-0.000
(0.5) 
Age (years) of 
household head
-0.005**
(3.3) 
-0.005**
(3.3) 
-0.003*
(2.2) 
 -0.003*
(2.3) 
-0.001
(1.3)  
-0.002
(1.4) 
Male household 
head
0.036
(0.8)  
0.039
(0.8)  
0.031
(0.6)  
0.035
(0.6)  
0.005
(0.1)  
 0.009
(0.1) 
Educated 
household head 
-0.198**
(4.0) 
-0.199**
(4.1) 
-0.215**
(4.6) 
 -0.219**
(4.7) 
-0.191**
(4.0) 
-0.193**
(4.0)
Household-size 0.006
(1.1)  
0.007
(1.2)  
0.000
(0.1)  
 0.001
(0.2)  
-0.000
(0.0)  
 0.000
(0.0) 
Household owning 
motorbike
-0.318**
(4.1) 
-0.321**
(4.2) 
-0.413**
(6.8)
-0.417**
(6.8) 
-0.439**
(6.7) 
-0.444**
(6.8)
Fixed term: 
community level
% of Hindus in 
the community
 
 0.013**
(4.7) 
0.004*
(2.1) 
 0.010**
(4.1)
Average age 
(years)
-0.045
(1.4)  
0.027
(1.2)  
-0.008
(0.3) 
% of males in the 
community
-0.015*
(2.1) 
 -0.014**
(3.3) 
-0.016**
(2.9)
% of educated 
household 
heads in the 
community
 
0.002
(0.3)  
0.003
(0.7)  
 
0.003
(0.7) 
% of households 
owning 
motorbike in the 
community
-0.000
(0.0)  
-0.021
(1.8)  
-0.008
(0.7) 
Random terms: 
community level
Constant 0.257 0.347 0.200 0.164 0.136 0.088 0.225 0.257 0.131
Intra-cluster 
correlation  
coefficient  0.204 0.257 0.166 0.141 0.119 0.081 0.184 0.204 0.116
The results are expressed as logits; **p<0.01; *p<0.05Ali M et al. Community participation in vaccination trials
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in both the trials. The inclusion of extra terms in 
Model 3 resulted in a marked reduction of cluster-
level variance from Model 1. The variance is sig-
nificantly different from zero, and the contrast be-
tween predicted levels for the ‘average’ individual 
from the best and the worst communities is now a 
difference between 51% and 93% for the typhoid 
vaccine trial, 66% and 90% for the cholera vaccine 
trial, and 44% and 86% for both the trials. The in-
tra-cluster correlation coefficient from the models 
ranged from 8% to 16%, indicating a significant 
amount of cluster-level variation in participation in 
the trials even after controlling for the individual 
and ecological characteristics.
The local empirical Bayes map shows a strong re-
gional pattern of participation in the trial with a 
higher rate of participation noted in the northern 
part compared to that in the southern part of the 
study area (Fig.). 
DISCUSSION
Our results illustrate that those who participated in 
the initial (typhoid) vaccine trial were more likely 
to participate in the subsequent (cholera) vaccine 
trial compared to those who did not participate in 
the initial trial, suggesting that the vaccine trials 
spaced out in an 18-month interval did not affect 
participation in a subsequent trial. One limitation 
of the study is that we were unable to locate and 
detect individuals included in the census but who 
migrated outside the area before the vaccine trials; 
however, the population is relatively stable with a 
<5% annual migration; thus, we believe that this 
will not substantially change the results of the anal-
ysis.  
The participation in the two trials was mainly in-
fluenced by various individual- and community-
level factors. These factors were mostly similar in 
both typhoid and cholera vaccine trials with only 
a few exceptions. The younger people were more 
likely to participate in both the trials than the older 
people. Typhoid fever is thought of as a disease of 
young children (15), and the incidence of cholera 
is higher in younger people (7), which could have 
encouraged the young people to participate in the 
trials. The negative association of participation with 
households owning a motorbike, which is an indi-
cator of economic status, may suggest that poorer 
people consider the campaign as an opportunity 
to get free vaccines (15). Participation in the trials 
was inversely related to the literacy and economic 
status of household head. In contrast, younger par-
ents were keen to vaccinate their children, which 
is promising. Compared to HIV vaccine trials (16), 
women were more likely to participate in vaccine 
trials against enteric diseases compared to men. 
Although religion at the individual level did not 
play any significant role in participation in all the 
trials, residents of predominantly Hindu commu-
nities were more likely to participate in the trials 
compared to residents of predominantly Muslim 
communities. This may be due to some precon-
ceived notions among Muslim communities relat-
ing to vaccines (2), which could perhaps result in 
lower participation by Muslims. The inclusion of 
community-level factors in the model resulted in 
narrower range between the worst and the best 
community participation, suggesting that, within 
the clusters, individuals may share common atti-
tudes and beliefs that may be targeted for behav-
ioural change interventions, leading to improved 
participation in vaccine trials and campaigns. 
The success of a vaccine trial or a vaccination cam-
paign depends on many factors, including mobili-
zation of the community. The social and cultural   
factors may also influence how vaccinations are 
interpreted (3). The high-coverage areas in the 
maps suggest the strong perceptions and commu-
nity behaviours towards prevention of diseases, 
thereby motivating people to get vaccinated (3,17). 
The maps also guide interpretation of communi-
ty-level obstacles to participation in vaccine trials 
and campaigns, and together with the outcomes of 
community-level analysis, they may suggest which 
factors discourage people not to participate.
The trials included in this analysis delivered vac-
cines through massive mobilization and recruit-
ment of individuals in a short period, which may 
be similar to vaccination campaigns. However, un-
like real public-health conditions, both the trials 
obtained informed consent from the community 
and individuals. Such procedures may have influ-
enced community behaviour in vaccine uptake. 
More recently, behavioural change and prevention 
models were developed to provide better under-
standing of participation and non-participation 
in vaccination programmes (18,19). These models 
explicitly articulate the presumed mechanisms by 
which the changes in behaviour are brought about 
and guide the development of behavioural change 
interventions accompanying vaccine campaigns. 
While various models (17,20) have been used for 
developing behavioural change interventions in 
vaccine campaigns (21), identification of factors 
that may impact the success of vaccination and 
identification of acceptable and convenient sites 
for vaccine delivery, respected sources for informa-
tion about the vaccine, e.g. health clinic personnel 
and community health volunteers, should be con-
sidered for successful vaccination campaigns. The 
lack of application of behavioural principles to un-
derstanding and designing strategies to introduce Ali M et al. Community participation in vaccination trials
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and improve vaccination programmes has limited 
the success of vaccination programmes and levels 
of participation in numerous contexts (21). Further 
studies of community behaviour to enhance the 
understanding and design of strategies to introduce 
and improve vaccination programmes would be 
useful. 
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